(NASDAQ: RNA) Avidity Biosciences's forecast annual revenue growth rate of 171.16% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 79.97%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.99%.
Avidity Biosciences's revenue in 2025 is $8,927,000.On average, 4 Wall Street analysts forecast RNA's revenue for 2025 to be $1,160,784,397, with the lowest RNA revenue forecast at $650,907,139, and the highest RNA revenue forecast at $1,458,514,144. On average, 4 Wall Street analysts forecast RNA's revenue for 2026 to be $3,130,983,875, with the lowest RNA revenue forecast at $1,060,737,559, and the highest RNA revenue forecast at $7,883,208,679.
In 2027, RNA is forecast to generate $25,816,061,962 in revenue, with the lowest revenue forecast at $12,152,677,354 and the highest revenue forecast at $40,561,157,804.